DAX
18.161,01 +243,73 (+1,36%) Euro Stoxx 50
5.006,85 +67,84 (+1,37%) Dow Jones 30
38.239,66 +153,86 (+0,40%) Gold
2.349,60 +7,10 (+0,30%) EUR/USD
1,0699 -0,0034 (-0,32%) Bitcoin EUR
58.871,06 -1.521,80 (-2,52%)
EPIGENOMICS AG NA O.N. (ECX.DE)
EPIGENOMICS AG NA O.N.
Geneststrasse 5
Berlin 10829
Germany
49 30 243 450
https://www.epigenomics.com
Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter:
Leitende Angestellte
| Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
|---|---|---|---|---|
| Mr. Jens Ravens | Executive VP of Finance & Member of Executive Board | 220,04k | N/A | 1970 |
| Mr. Hansjorg Plaggemars | Member of Executive Board | N/A | N/A | N/A |
| Frederic Hilke | Investor Relations Officer | N/A | N/A | N/A |
| Dr. Noel Thomas Doheny | Chief Executive Officer of Epigenomics Inc. | N/A | N/A | N/A |
Beschreibung
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. The company was founded in 1998 and is headquartered in Berlin, Germany.
Corporate Governance
EPIGENOMICS AG NA O.N.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.
